OwnershipPublicly listed · NYSE: LCTXSEC EDGAR company record and tickers file (NYSE: LCTX) · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessVerified public listingListed as NYSE: LCTX, per the SEC's company tickers file. A listing means shares trade publicly; it says nothing about whether they are a good investment.Source · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Next scheduled recheck: Nov 27, 2026.
3developments published
—US federal obligations on record
0federal awards
Aug 6, 2026latest development
Timeline
- Aug 6, 2026 · Reported results
LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Company-reported - Jun 9, 2026 · Shareholder vote
Lineage Cell Therapeutics reports results of a shareholder vote (Form 8-K, Item 5.07)
Regulatory filing - May 12, 2026 · Reported results
LINEAGE CELL THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Company-reported
Profile
- Legal name
- Lineage Cell Therapeutics, Inc.
- Listing
- NYSE LCTX
- SEC filer
- CIK 0000876343 ↗
- SEC industry code
- Biological Products, (No Diagnostic Substances)
- Incorporated
- CA
- Coverage
- Filings + federal awards
Mix of developments
Watch Lineage Cell Therapeutics
Anything new from Lineage Cell Therapeutics lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digest